Article Text

Download PDFPDF
Rivaroxaban-related acute kidney injury in a patient with IgA vasculitis
  1. Yoshihiko Fujino1,
  2. Chisato Takahashi1,
  3. Kensuke Mitsumoto1 and
  4. Takashi Uzu2
  1. 1 Nephrology, Nippon Life Hospital, Osaka, Japan
  2. 2 Nephrology and Blood Purification, Nippon Life Hospital, Osaka, Japan
  1. Correspondence to Dr Takashi Uzu, takuzu{at}


Anticoagulants have recently been recognised as a cause of acute kidney injury (AKI). We describe the case of a 75-year-old man with IgA vasculitis and atrial fibrillation treated with rivaroxaban, who presented with macroscopic haematuria and an acute decline in renal function. Two months before referral, he noted palpable purpuric lesions and was diagnosed with IgA vasculitis based on skin biopsy findings; the skin lesion disappeared following treatment with a steroid external preparation. Renal biopsy revealed glomerular haemorrhage and red blood cell casts. Although rivaroxaban was withdrawn, his kidney function worsened and he was started on haemodialysis. His renal function did not recover. To the best of our knowledge, this is the first case of direct oral anticoagulant (DOAC)-related AKI in systemic vasculitis. During DOAC therapy, close monitoring of a patient’s urinalysis results and their renal function may be required for patients with systemic vasculitis to avoid AKI.

  • arrhythmias
  • renal system
  • general practice / family medicine
  • safety

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Patient consent for publication Obtained.

  • Contributors YF, CT, KM and TU treated the patients. YF, CT and KM collected data. YF and TU drafted the report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.